An in-depth look to HYLORIS PHARMACEUTICALS SA NPV operating, investing, and financing activities

0AB6 free cash flow for H2 24 is -3.25 M EUR. For 2024, 0AB6 free cash flow was -6.18 M EUR and operating cash flow was -6.15 M EUR.